Mandate

Vinge advises Borlänge municipality in conjunction with the European Commission’s state aid review of the real estate transfer to IKEA and Ikano

May 07, 2012

Vinge has advised Borlänge municipality and the municipally-owned company, Norra Backa i Borlänge AB in connection with the European Commission’s state aid review of the real estate transfer to IKEA and Ikano.

In 2010, Norra Backa i Borlänge AB and Borlänge municipality sold two properties to IKEA and Ikano for construction of, among other things, an IKEA superstore. However, in 2011 a complaint was submitted to the European Commission alleging that the properties were sold well below market value and that the municipality had thereby provided IKEA and Ikano with unlawful state aid. Following two reviews with questions being submitted to the European Commission, the Commission has now stated that the transaction does not constitute any form of state aid for the benefit of the purchasers.

Vinge’s team consisted of partner Martin Johansson and associate Hanna Danwall at Vinge’s Brussels office.

“We have once again received confirmation that the municipality acted correctly and this matter may now be allowed to rest. A lot of people have been waiting for this decision, including Borlänge residents and investors. An IKEA superstore has a significant value, both in terms of Borlänge’s attractiveness at various different levels and for the future prospects of our municipality” says Jan Bohman, the chairman of the municipal executive board and chairman of Norra Backa AB, in a press release from Borlänge municipality. 

Related

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024

Vinge advises Triton in connection with the divestment of Norstat to Nalka Invest

Vinge advises Triton Smaller Mid-Cap Fund I (“Triton”) in connection with the divestment of Norstat, a leading data collector for market research, to Nalka Invest.
April 12, 2024